Ocugen Inc (OCGN) Stock Price, Quote & News

Latest News on OCGN

Jan 16, 2025, 7:30 AM EST - 1 day ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 13, 2025, 6:30 AM EST - 4 days ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Dec 19, 2024, 6:38 AM EST - 4 weeks ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 11, 2024, 7:02 AM EST - 5 weeks ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 27, 2024, 7:09 AM EST - 7 weeks ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 7:30 AM EST - 2 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 19, 2024, 7:02 AM EST - 2 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 8, 2024, 10:18 AM EST - 2 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:45 AM EST - 2 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 7, 2024, 6:30 AM EST - 2 months ago

Ocugen Secures $30 Million in Debt Funding

Oct 28, 2024, 6:30 AM EDT - 2 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 22, 2024, 7:02 AM EDT - 3 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 17, 2024, 7:30 AM EDT - 3 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 9, 2024, 6:30 AM EDT - 3 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 2, 2024, 6:30 AM EDT - 3 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Sep 24, 2024, 7:30 AM EDT - 4 months ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 8:00 AM EDT - 4 months ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 2:25 AM EDT - 4 months ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 9, 2024, 6:30 AM EDT - 4 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Sep 5, 2024, 7:00 AM EDT - 4 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Sep 3, 2024, 7:30 AM EDT - 4 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 6:30 AM EDT - 5 months ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Aug 26, 2024, 7:02 AM EDT - 5 months ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Aug 20, 2024, 9:00 AM EDT - 5 months ago

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Aug 8, 2024, 6:45 AM EDT - 5 months ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Aug 5, 2024, 6:30 AM EDT - 5 months ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Aug 2, 2024, 3:22 PM EDT - 6 months ago

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Jul 31, 2024, 9:15 PM EDT - 6 months ago

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Jul 31, 2024, 4:15 PM EDT - 6 months ago

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Jul 29, 2024, 7:02 AM EDT - 6 months ago

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Jul 25, 2024, 6:30 AM EDT - 6 months ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

Jul 1, 2024, 11:07 AM EDT - 7 months ago

Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles

Jun 21, 2024, 7:00 AM EDT - 7 months ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Jun 20, 2024, 6:30 AM EDT - 7 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

Jun 10, 2024, 10:20 AM EDT - 7 months ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Jun 9, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Touch Base With the Firm Before the June 10th Deadline

Jun 7, 2024, 11:00 AM EDT - 8 months ago

Reminder for the June 10th Deadline: The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Reach Out

Jun 6, 2024, 11:00 AM EDT - 8 months ago

June 10th Deadline Reminder: The Schall Law Firm Invites Ocugen, Inc. Investors With Losses To Connect

Jun 6, 2024, 9:40 AM EDT - 8 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Jun 5, 2024, 10:40 AM EDT - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Jun 4, 2024, 11:45 AM EDT - 8 months ago

FINAL DEADLINE NEXT WEEK: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm

Jun 4, 2024, 11:00 AM EDT - 8 months ago

OCGN DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Jun 3, 2024, 12:30 PM EDT - 8 months ago

OCGN DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Jun 2, 2024, 11:00 AM EDT - 8 months ago

IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

May 31, 2024, 11:00 AM EDT - 8 months ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

May 31, 2024, 8:36 AM EDT - 8 months ago

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

May 29, 2024, 12:53 PM EDT - 8 months ago

Ocugen stock price analysis: good progress but a risky pattern forms

May 29, 2024, 7:15 AM EDT - 8 months ago

Ocugen to Present at BIO International Convention 2024

May 28, 2024, 7:02 AM EDT - 8 months ago

Market Cap	208.29M
Revenue (ttm)	6.04M
Net Income (ttm)	-63.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,044.37%
Debt to Equity Ratio	0.07

Volume	4,950,000
Avg Vol	4,986,246
Day's Range	N/A - N/A
Shares Out	291.32M
Stochastic %K	7%
Beta	3.85
Analysts	Strong Sell
Price Target	$6.25